⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26050938 | 0.83 | — | — | |
| SCHEMBL21191693 | 0.81 | — | — | |
| SCHEMBL22726007 | 0.72 | — | — | |
| SCHEMBL2737281 | 0.70 | — | — | |
| SCHEMBL1106162 | 0.70 | — | — | |
| SCHEMBL1104710 | 0.70 | — | — | |
| SCHEMBL21720631 | 0.68 | — | — | |
| SCHEMBL21720240 | 0.68 | — | — | |
| SCHEMBL14287424 | 0.68 | — | — | |
| SCHEMBL27276293 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-11384048-B2 | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20220009936-A1 | RIP1K INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-01-13 | — | — | US | disclosed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20210061755-A1 | AROMATIC VINYL OR AROMATIC ETHYL DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-9066947-B2 | Indolyl-substituted pyrazino[1,2-b]isoquinolines for cancer treatment | EVEREST BIOSCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140235644-A1 | INDOLYL-SUBSTITUTED PYRAZINO-QUINOLINES AND THEIR USE FOR THE TREATMENT OF CANCER | EVEREST BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8754086-B2 | Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer | EVEREST BIOSCIENCES, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120157461-A1 | Indolyl-Substituted Pyrazino-Quinolines and Their Use for the Treatment of Cancer | ONKILL AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | CHACKALAMANNIL SAMUEL (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | CHACKALAMANNIL SAMUEL (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153664-B2 | thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer | SCHERING CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |